| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Leachianone A does not have a single defined target. It is a phenolic compound with potential anti-malarial and anti-inflammatory properties. Its antioxidant and anti-inflammatory activities suggest it may interact with pathways involved in oxidative stress and inflammation.
|
|---|---|
| ln Vitro |
Leachianone A (0–20 μg/ml; 24-72 hours) significantly reduces HepG2 cell survival in a time- and dose-dependent manner; IC50 values for cells treated for 24 hours, 48 hours, and 72 hours, respectively, are 6.9 μg/ml, 3.4 μg/ml, and 2.8 μg/ml [1]. Leachianone A (10-30 μg/ml; 48 hours) demonstrated that cells were predominantly in the early stages of apoptosis at low concentrations of LA (10 μg/ml), while higher concentrations induced apoptosis transformation. The cell population transitions into apoptosis/necrosis's final stage [1]. In HepG2 cells, leachianone A (10–30 μg/ml; 48 hours) reduces caspase-3 precursors in a dose-dependent manner, along with caspase-8 and -9 precursors' protein levels and two downstream substrates: inhibitor of caspase-activated DNase (ICAD) and poly-ADP ribose polymerase (PARP) [1].
In vitro, Leachianone A has been studied for its potential anti-malarial and anti-inflammatory properties. It possesses strong antioxidant and anti-inflammatory properties, helping to reduce oxidative stress and suppress pro-inflammatory mediators. Its activity has been evaluated in HepG2 cells in vitro. |
| ln Vivo |
In comparison to vehicle-only nude mice, leachianone A (iv; 20 mg/kg, 30 mg/kg; once daily; 30 days) dramatically decreased tumor volume in LA-treated nude mice by 17–54% [1].
In vivo, the anti-inflammatory and antioxidant activities of Leachianone A suggest it may have therapeutic potential. However, specific in vivo efficacy data are not extensively documented. The compound is primarily used as a research tool. |
| Enzyme Assay |
For in vitro cell-based assays, the activity of Leachianone A can be evaluated using cell lines like HepG2. Cells are treated with the compound, and its effects on cell viability, oxidative stress markers, and inflammatory mediators are measured. Its anti-malarial activity can be assessed using Plasmodium falciparum cultures.
|
| Cell Assay |
Cell viability assay[1]
Cell Types: HepG2 Cell Tested Concentrations: 0 μg/ml, 2 μg/ml, 4 μg/ml, 6 μg/ml, 8 μg/ml, 10 μg/ml, 12 μg/ml, 14 μg /ml, 16 μg/ml, 18 μg/ml, 20 μg/ml Incubation Duration: 24-72 hrs (hours) Experimental Results: Inhibited HepG2 cell survival. Apoptosis analysis [1] Cell Types: HepG2 Cell Tested Concentrations: 48 hrs (hours) Incubation Duration: 10, 20 and 30 μg/ml Experimental Results: Proportion of Annexin V-stained cells in the early and late stages of apoptosis induced. Western Blot Analysis [1] Cell Types: HepG2 Cell Tested Concentrations: 48 hrs (hours) Incubation Duration: 10, 20 and 30 μg/ml Experimental Results: Reduce the protein expression of caspase-3, caspase-8 and -9, and reduce the protein expression of ICAD and PARP. For in vitro cell-based assays, the activity of Leachianone A can be evaluated using cell lines like HepG2. Cells are treated with the compound, and its effects on cell viability, oxidative stress markers, and inflammatory mediators are measured. Its anti-malarial activity can be assessed using Plasmodium falciparum cultures. |
| Animal Protocol |
Animal/Disease Models: human liver cancer HepG2 cells male nude mice [1]
Doses: 20 mg/kg; 30 mg/kg Route of Administration: intravenous (iv) (iv)injection; 20 mg/kg, 30 mg/kg; one time/day; 30-day Experimental Results: Inhibition in vivo Tumor growth. For in vivo animal studies, Leachianone A is typically administered orally or intraperitoneally. To study its anti-inflammatory effects, animal models of acute or chronic inflammation can be used. Its anti-malarial activity can be evaluated in mouse models of malaria. |
| ADME/Pharmacokinetics |
Leachianone A has a molecular weight of 438.5 and a formula of C26H30O6. It is typically stored at 2-8°C. Detailed pharmacokinetic parameters are not publicly available.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Leachianone A are limited. As a natural compound, it is generally considered to have a favorable safety profile. However, comprehensive toxicological studies have not been published. The compound is used for research purposes only and is not intended for human use.
|
| References |
|
| Additional Infomation |
Leachianone A is a trihydroxyflavanone with the structure (2S)-flavanone, substituted with a lavenderyl group at the 8' position, hydroxyl groups at the 5', 7', and 4' positions, and a methoxy group at the 2' position. It was isolated from the roots of Sophora flavescens and Sophora leachiana and possesses antitumor and antimalarial activities. It is both a metabolite and an antitumor and antimalarial agent. Leachianone A is a monomethoxyflavanone, a trihydroxyflavanone, and a member of the 4'-hydroxyflavanone family. Functionally, it is related to (2S)-flavanones. Leachianone A has been reported to exist in Sophora stenophylla, other Sophora species, and other organisms with relevant data.
Leachianone A is a research compound with no clinical trial or regulatory approval status. It is a natural product isolated from Sophora flavescens and is used as a research tool. It is commercially available from chemical suppliers for research purposes only. |
| Molecular Formula |
C26H30O6
|
|---|---|
| Molecular Weight |
438.5128
|
| Exact Mass |
438.204
|
| CAS # |
97938-31-3
|
| PubChem CID |
44593449
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
649.7±55.0 °C at 760 mmHg
|
| Flash Point |
218.3±25.0 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.597
|
| Source |
Originated from plants: Leguminosae Sophora flavescens Aiton
|
| LogP |
7.27
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
32
|
| Complexity |
698
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(=CC[C@H](CC1=C2C(=C(C=C1O)O)C(=O)C[C@H](O2)C3=C(C=C(C=C3)O)OC)C(=C)C)C
|
| InChi Key |
YLTPWCZXKJSORQ-GYCJOSAFSA-N
|
| InChi Code |
InChI=1S/C26H30O6/c1-14(2)6-7-16(15(3)4)10-19-20(28)12-21(29)25-22(30)13-24(32-26(19)25)18-9-8-17(27)11-23(18)31-5/h6,8-9,11-12,16,24,27-29H,3,7,10,13H2,1-2,4-5H3/t16-,24+/m1/s1
|
| Chemical Name |
(2S)-5,7-dihydroxy-2-(4-hydroxy-2-methoxyphenyl)-8-[(2R)-5-methyl-2-prop-1-en-2-ylhex-4-enyl]-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~228.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (11.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2804 mL | 11.4022 mL | 22.8045 mL | |
| 5 mM | 0.4561 mL | 2.2804 mL | 4.5609 mL | |
| 10 mM | 0.2280 mL | 1.1402 mL | 2.2804 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
